Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 20/20 | 0.41 |
| ▸ | BCL2L11 | O43521 | 14/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21993734 | 0.86 | MAP3K14 (0.35) | — | |
| SCHEMBL21930487 | 0.85 | MCL1 (0.41) | MCL1BCL2L11CCND1 | |
| SCHEMBL30261895 | 0.85 | MCL1 (0.41) | MCL1BCL2L11CCND1 | |
| SCHEMBL21930197 | 0.81 | TAS2R14 (0.40) | MCL1BCL2L11 | |
| SCHEMBL30261896 | 0.81 | TAS2R14 (0.40) | MCL1BCL2L11 | |
| SCHEMBL21930396 | 0.81 | TAS2R14 (0.40) | MCL1BCL2L11 | |
| SCHEMBL25670137 | 0.80 | MCL1 (0.42) | MCL1BCL2L11CCND1 | |
| SCHEMBL24461727 | 0.78 | MCL1 (0.42) | MCL1BCL2L11CCND1 | |
| SCHEMBL29414585 | 0.78 | MCL1 (0.42) | MCL1BCL2L11CCND1 | |
| SCHEMBL22894800 | 0.78 | MCL1 (0.42) | MCL1BCL2L11CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212191-A1 | SPIRO-SULFONIMIDAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212191-A1 | SPIRO-SULFONIMIDAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | MCL1, BCL9, BCL2L1 | MCL1 1/4885BCL2L11 7/4885CCND1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.